Moritz Robert L, Skandarajah Anita R, Ji Hong, Simpson Richard J
Joint Proteomics Laboratory Ludwig Institute for Cancer Research (Melbourne Branch), The Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia.
Comp Funct Genomics. 2005;6(4):236-43. doi: 10.1002/cfg.477.
This review deals with the application of a new prefractionation tool, free-flow electrophoresis (FFE), for proteomic analysis of colorectal cancer (CRC). CRC is a leading cause of cancer death in the Western world. Early detection is the single most important factor influencing outcome of CRC patients. If identified while the disease is still localized, CRC is treatable. To improve outcomes for CRC patients there is a pressing need to identify biomarkers for early detection (diagnostic markers), prognosis (prognostic indicators), tumour responses (predictive markers) and disease recurrence (monitoring markers). Despite recent advances in the use of genomic analysis for risk assessment, in the area of biomarker identification genomic methods alone have yet to produce reliable candidate markers for CRC. For this reason, attention is being directed towards proteomics as a complementary analytical tool for biomarker identification. Here we describe a proteomics separation tool, which uses a combination of continuous FFE, a liquid-based isoelectric focusing technique, in the first dimension, followed by rapid reversed-phase HPLC (1-6 min/analysis) in the second dimension. We have optimized imaging software to present the FFE/RP-HPLC data in a virtual 2D gel-like format. The advantage of this liquid based fractionation system over traditional gel-based fractionation systems is the ability to fractionate large quantity protein samples. Unlike 2D gels, the method is applicable to both high-M(r) proteins and small peptides, which are difficult to separate, and in the case of peptides, are not retained in standard 2D gels.
本综述探讨了一种新型预分级工具——自由流电泳(FFE)在结直肠癌(CRC)蛋白质组学分析中的应用。CRC是西方世界癌症死亡的主要原因。早期检测是影响CRC患者预后的唯一最重要因素。如果在疾病仍局限时被发现,CRC是可治疗的。为了改善CRC患者的预后,迫切需要识别用于早期检测(诊断标志物)、预后(预后指标)、肿瘤反应(预测标志物)和疾病复发(监测标志物)的生物标志物。尽管在利用基因组分析进行风险评估方面取得了最新进展,但在生物标志物识别领域,仅靠基因组方法尚未产生可靠的CRC候选标志物。因此,蛋白质组学作为生物标志物识别的补充分析工具正受到关注。在此,我们描述了一种蛋白质组学分离工具,它在第一维结合了连续FFE(一种基于液体的等电聚焦技术),在第二维结合了快速反相高效液相色谱(每次分析1 - 6分钟)。我们优化了成像软件,以虚拟二维凝胶样格式呈现FFE/RP - HPLC数据。这种基于液体的分级系统相对于传统基于凝胶的分级系统的优势在于能够分级大量蛋白质样品。与二维凝胶不同,该方法适用于高相对分子质量(M(r))蛋白质和难以分离的小肽,就小肽而言,它们不会保留在标准二维凝胶中。